A Phase II Pilot Study of yttriuM-90 in Combination With capEcitabine and aTezolizumab for oligomEtastatic cOlorectal Cancer With unResectable lIver MeTastasEs (METEORITE)
Latest Information Update: 17 Apr 2025
At a glance
- Drugs Atezolizumab (Primary) ; Yttrium-90 (Primary) ; Capecitabine
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms METEORITE
Most Recent Events
- 09 Apr 2025 Status changed from not yet recruiting to recruiting.
- 04 Feb 2025 Planned initiation date changed from 30 Dec 2024 to 1 Mar 2025.
- 25 Nov 2024 Planned initiation date changed from 30 Aug 2024 to 30 Dec 2024.